The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 9, 2010, Pages 1369-1375

  Ebner, Florian ^a   Schremmer Danninger, Elisabeth ^b   Rehbock, Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

R72P rs1042522 (gene TP53); S31R ss4388499 (gene p21)

Indexed keywords

PROTEIN P21; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CHROMOSOME 6P; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; P21 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR SUPPRESSOR GENE; BREAST TUMOR; GENETICS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENOTYPE; GERMANY; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77955505936     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0788-9     Document Type: Article

References (44)

1. M Asada T Yamada H Ichijo D Delia K Miyazono K Fukumuro S Mizutani 1999 Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation 2 EMBO J 18 1223 1234 10.1093/emboj/18.5.1223 1:CAS:528:DyaK1MXhvFOksL8%3D 10064589
2. R Bahl S Arora N Nath M Mathur NK Shukla R Ralhan 2000 Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer Oncogene 19 323 328 10.1038/sj.onc.1203325 1:CAS:528:DC%2BD3cXpvVSgsQ%3D%3D 10656678
3. SJ Baker ER Fearon JM Nigro SR Hamilton AC Preisinger JM Jessup P van Tuinen DH Ledbetter DF Baker Y Nakamura R White B Vogelstein 1989 Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas Science 244 217 221 10.1126/science.2649981 1:CAS:528:DyaL1MXit12gt74%3D 2649981
4. A Bansal D van den Boom S Kammerer C Honisch G Adam CR Cantor P Kleyn A Braun 2002 Association testing by DNA pooling: an effective initial screen Proc Natl Acad Sci USA 99 16871 16874 10.1073/pnas.262671399 1:CAS:528: DC%2BD3sXhvV2nsg%3D%3D 12475937
5. KH Buetow M Edmonson R MacDonald R Clifford P Yip J Kelley DP Little R Strausberg H Koester CR Cantor A Braun 2001 High-throughput development and characterization of a genome wide collection of gene-based single nucleotide polymorphism markers by chip-based matrix assisted laser desorption/ionization time-of-flight mass spectrometry Proc Natl Acad Sci USA 98 581 584 10.1073/pnas.021506298 1:CAS:528:DC%2BD3MXnslKgug%3D%3D 11136232
6. B Calabretta L Kaczmarek L Selleri G Torelli PM Ming SC Ming WE Mercer 1986 Growth-dependent expression of human Mr 53, 000 tumor antigen messenger RNA in normal and neoplastic cells Cancer Res 46 5738 5742 1:CAS:528: DyaL28Xmt1ekt78%3D 3019534
7. A Castells P Puig J Móra J Boadas L Boix E Urgell M Solé G Capellà F Lluis L Fernández-Cruz S Navarro A Farré 1999 K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance J Clin Oncol 17 578 584 1:CAS:528:DyaK1MXht1Wmu7w%3D 10080602
8. M Chedid P Michieli C Lengel K Huppi D Givol 1994 A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1 Oncogene 9 3021 3024 1:CAS:528:DyaK2MXhtFWjtbs%3D 8084608
9. T Crook S Crossland MR Crompton P Osin BA Gusterson 1997 P53 mutations in BRCA1-associated familial breast cancer Lancet 350 638 639 10.1016/S0140- 6736(05)63327-2 1:CAS:528:DyaK2sXmt1Wltbc%3D 9288052
10. W Deppert G Buschhausen-Denker T Patschinsky K Steinmeyer 1990 Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells II. Requirement for cell cycle progression Oncogene 5 1701 1706 1:CAS:528:DyaK3MXlvFGqtQ%3D%3D 2267136
11. R Doll R Peto 1981 The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today J Natl Cancer Inst 66 1191 1308 1:STN:280:DyaL3M3hvFShsA%3D%3D 7017215
12. AM Dunning CS Healey PD Pharoah MD Teare BA Ponder DF Easton 1999 A systematic review of genetic polymorphisms and breast cancer risk Cancer Epidemiol Biomarkers Prev 8 843 854 1:CAS:528:DyaK1MXns1CrtLw%3D 10548311
13. WS el Deiry T Tokino VE Velculescu DB Levy R Parsons JM Trent D Lin WE Mercer KW Kinzler B Vogelstein 1993 WAF1, a potential mediator of p53 tumor suppression Cell 75 817 825 10.1016/0092-8674(93)90500-P 1:CAS:528: DyaK2cXpslGguw%3D%3D 8242752
14. JK Field DA Spandidos 1990 The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review) 1 Anticancer Res 10 1 22 1:CAS:528:DyaK3cXlsVKjt7w%3D 2185684
15. B Gulbis P Galand 1993 Immunodetection of the p21-ras products in human normal and preneoplastic tissues and solid tumors: a review Hum Pathol 24 1271 1285 10.1016/0046-8177(93)90260-N 1:CAS:528:DyaK2cXis1Krt7k%3D 8276374
16. T Hachiya Y Kuriaki Y Ueoka J Nishida K Kato N Wake 1999 WAF1 genotype and endometrial cancer susceptibility Gynecol Oncol 72 187 192 10.1006/gyno.1998.5247 1:CAS:528:DyaK1MXhtFWmt74%3D 10021299
17. CR Hoyal S Kammerer RB Roth R Reneland G Marnellos M Kiechle U Schwarz-Boeger LR Griffiths F Ebner J Rehbock MR Nelson A Braun 2005 Genetic polymorphisms in DPF3 associated with risk of breast cancer and lymph node metastases J Carcinog 4 13 10.1186/1477-3163-4-13 16109180
18. S Kammerer RB Roth R Reneland G Marnellos CR Hoyal NJ Markward F Ebner M Kiechle U Schwarz-Boeger LR Griffiths C Ulbrich K Chrobok G Forster GM Praetorius P Meyer J Rehbock CR Cantor MR Nelson A Braun 2004 Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus Cancer Res 64 8906 8910 10.1158/0008-5472.CAN-04-1788 1:CAS:528:DC%2BD2cXhtVOmsLzE 15604251
19. MB Kastan O Onyekwere D Sidransky B Vogelstein RW Craig 1991 Participation of p53 protein in the cellular response to DNA damage Cancer Res 51 6304 6311 1:CAS:528:DyaK38XhvFSltg%3D%3D 1933891
20. R Kaul S Mukherjee F Ahmed MK Bhat R Chhipa S Galande S Chattopadhyay 2003 Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice Int J Cancer 103 606 615 10.1002/ijc.10881 1:CAS:528:DC%2BD3sXmtFKgtA%3D%3D 12494467
21. C Keshava BL Frye MS Wolff EC McCanlies A Weston 2002 Waf-1 (p21) and p53 polymorphisms in breast cancer Cancer Epidemiol Biomarkers Prev 11 127 130 1:CAS:528:DC%2BD38XhvFGiur8%3D 11815410
22. SJ Kuerbitz BS Plunkett WV Walsh MB Kastan 1992 Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proc Natl Acad Sci USA 89 7491 7495 10.1073/pnas.89.16.7491 1:CAS:528:DyaK38Xls1Kkt7c%3D 1323840
23. A Lavigueur V Maltby D Mock J Rossant T Pawson A Bernstein 1989 High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene Mol Cell Biol 9 3982 3991 1:CAS:528:DyaL1MXlsVOrtbw%3D 2476668
24. Y Li D Dowbenko LA Lasky 2002 AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival 1 J Biol Chem 277 11352 11361 10.1074/jbc.M109062200 1:CAS:528:DC%2BD38Xis1KgsLs%3D 11756412
25. J Lukas S Groshen B Saffari N Niu A Reles WH Wen J Felix LA Jones FL Hall MF Press 1997 WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium Am J Pathol 150 167 175 1:CAS:528: DyaK2sXoslWqsQ%3D%3D 9006333
26. D Malkin FP Li LC Strong JF Fraumeni Jr CE Nelson DH Kim J Kassel MA Gryka FZ Bishoff MA Tainsky, et al. 1990 Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science 250 1233 1238 10.1126/science.1978757 1:CAS:528:DyaK3MXjslSisw%3D%3D 1978757
27. JA McCubrey SL Abrams G Ligresti N Misaghian EW Wong LS Steelman J Bäsecke J Troppmair M Libra F Nicoletti S Molton M McMahon C Evangelisti AM Martelli 2008 Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance Leukemia 22 2080 2090 10.1038/leu.2008.207 1:CAS:528: DC%2BD1cXhtlGrur7K 18685611
28. WE Mercer C Avignolo R Baserga 1984 Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies Mol Cell Biol 4 276 281 1:CAS:528:DyaL2cXhtFymtbg%3D 6366518
29. J Milner F McCormick 1980 Lymphocyte stimulation: concanavalin A induces the expression of a 53 K protein Cell Biol Int Rep 4 663 667 10.1016/0309-1651(80)90205-2 1:CAS:528:DyaL3cXlsVOqtr4%3D 7397796
30. PP Osin SR Lakhani 1999 The pathology of familial breast cancer: Immunohistochemistry and molecular analysis Breast Cancer Res 1 36 40 10.1186/bcr11 1:CAS:528:DC%2BD3cXlsFKgsbw%3D 11250681
31. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, Sicotte H, Staats B, Acharya M, Crenshaw A, Eckert A, Puri V, Gerhard DS, Chanock SJ (2006) SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 34:617-621
32. BL Powell IL van Staveren P Roosken F Grieu EM Berns B Iacopetta 2002 Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer Carcinogenesis 23 311 315 10.1093/carcin/23.2.311 1:CAS:528:DC%2BD38XitVGltbs%3D 11872638
33. NC Reich AJ Levine 1984 Growth regulation of a cellular tumour antigen, p53, in nontransformed cells Nature 308 199 201 10.1038/308199a0 1:CAS:528:DyaL2cXhsFCqtbo%3D 6366574
34. Sauer H (ed) Manual Mammakarzinom 2005, Tumorzentrum München, Zuckschwert Verlag München, Wien, New York
35. O Shohat M Greenberg D Reisman M Oren V Rotter 1987 Inhibition of cell growth mediated by plasmids encoding p53 anti-sense Oncogene 1 277 283 1:CAS:528:DyaL1cXhvFKlsw%3D%3D 2455263
36. JM Silva G Dominguez JM Garcia R Gonzalez MJ Villanueva F Navarro M Provencio S San Martin P Espana F Bonilla 1999 Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations Cancer Res 59 3251 3256 1:CAS:528:DyaK1MXksVGjsLc%3D 10397273
37. A Själander R Birgander G Hallmans S Cajander P Lenner L Athlin G Beckman L Beckman 1996 p53 polymorphisms and haplotypes in breast cancer Carcinogenesis 17 1313 1316 10.1093/carcin/17.6.1313 8681448
38. H Soehnge A Ouhtit HN Ananthaswamy 1997 Mechanisms of induction of skin cancer by UV radiation Front Biosci 2 d538 d551 1:CAS:528:DyaK1cXhtVOgsbo%3D 9343491
39. K Steinmeyer H Maacke W Deppert 1990 Cell cycle control by p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. I. Regulation of p53 expression Oncogene 5 1691 1699 1:CAS:528:DyaK3MXlvFGqtA%3D%3D 2267135
40. T Takahashi MM Nau I Chiba MJ Birrer RK Rosenberg M Vinocour M Levitt H Pass AF Gazdar JD Mima 1989 p53: a frequent target for genetic abnormalities in lung cancer Science 246 491 494 10.1126/science.2554494 1:CAS:528: DyaL1MXmt1Knu7Y%3D 2554494
41. The Breast Cancer Association Consortium 2006 Commonly studies single-nucleotide polymorphisms and breast cancer: results from the breast cancer association consortium J Natl Cancer Inst 98 1382 1396 10.1093/jnci/djj374
42. B Vogelstein ER Fearon SR Hamilton SE Kern AC Preisinger M Leppert Y Nakamura R White AM Smits JL Bos 1988 Genetic alterations during colorectal-tumor development N Engl J Med 319 525 532 1:STN:280: DyaL1czgt1aqtQ%3D%3D 2841597
43. RH Weiss D Marshall L Howard AM Corbacho AT Cheung ET Sawai 2003 Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1) Cancer Lett 189 39 48 10.1016/S0304-3835(02)00495-0 1:CAS:528:DC%2BD38XoslGis7c%3D 12445676
44. D Yair G Ben Baruch A Chetrit T Friedman G Hirsh Yechezkel WH Gotlieb A Fishman U Beller A Bar-Am E Fishman 2000 p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations BJOG 107 849 854 10.1111/j.1471-0528.2000.tb11082.x 1:CAS:528:DC%2BD3cXlsVCmt7k%3D 10901555